Technetium Tc-99m pyrophosphate is a radiopharmaceutical diagnostic agent used for diagnostic imaging scans for the bones, heart, and gastrointestinal tract. A radionuclide imaging agent used primarily in scintigraphy or tomography of the heart to evaluate the extent of the necrotic myocardial process.
- Mechanism
- Curator reviewed · 1 reference
It is thought that technetium Tc-99m pyrophosphate is adsorbed onto the surface of amorphous calcium phosphate deposits, insoluble hydroxyapatite crystals, and possibly other organic macromolecules. This would result in selective localization to necrotic muscle tissue such as that of a myocardial infarction where calcium deposition has begun as a result of cell damage. In areas of altered osteogenesis where hydroxyapatite formation is actively occuring, the surface area to volume ratio is high and favors a greater amount of technetium Tc-99m pyrophosphate to the surface of the crystals than in other areas of bone where crystal formation is less active. The localization of technetium Tc-99m pyrophosphate to these areas allows for their specific radioimaging.
- Primary indication
- For use as a skeletal imaging agent used to demonstrate areas of altered osteogenesis, and a cardiac imaging agent used as an adjunct in the diagnosis of acute myocardial infarction.Curator reviewed · 4 structured indications
- Formula / weight
- O7P2Tc · 272.847 g/mol (avg)
- First approval
- United States, 1987
- Also known as
- Technetium (99mTc) pyrophosphate · Technetium TC 99M Pyrophosphate
Resolves to
OOGKGVXDDGJCPO-NLQOEHMXSA-JSMILES[99Tc+4].[O-]P([O-])(=O)OP([O-])([O-])=OWhat you can answer from here — as of April 02, 2025
Which other approved drugs treat the same conditions as Technetium Tc-99m pyrophosphate, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account